Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy

Khatami, Fatemeh; Tavangar, Seyed Mohammad

doi:10.1007/s40200-018-0334-x

Cited by 11 publications

(9 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite advances in early detection and treatment, the number of new cancer cases and deaths is still increasing globally [ 1 ]. Moreover, each tumor possesses a unique genetic profile and has the potential to develop drug resistance and spread to distant sites [ 2 ]. Hence, new strategies for personalized treatment guided by diagnostic, predictive, and prognostic biomarkers are urgently needed to reverse increasing incidence and mortality rates.…”

Section: Introductionmentioning

confidence: 99%

“…Robust and accessible biomarkers for immediate assessment of tumor response and monitoring of minimal residual disease (MRD) are crucial to improving patient outcomes. Thus, recently published research articles and reviews have highlighted the potential of liquid biopsy-based biomarkers as a real-time reflection of the tumor burden with diagnostic, prognostic, and predictive information to guide cancer management [ 2 – 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance

et al. 2023

View full text Add to dashboard Cite

Background Despite advances in early detection and therapies, cancer is still one of the most common causes of death worldwide. Since each tumor is unique, there is a need to implement personalized care and develop robust tools for monitoring treatment response to assess drug efficacy and prevent disease relapse. Main body Recent developments in liquid biopsies have enabled real-time noninvasive monitoring of tumor burden through the detection of molecules shed by tumors in the blood. These molecules include circulating tumor nucleic acids (ctNAs), comprising cell-free DNA or RNA molecules passively and/or actively released from tumor cells. Often highlighted for their diagnostic, predictive, and prognostic potential, these biomarkers possess valuable information about tumor characteristics and evolution. While circulating tumor DNA (ctDNA) has been in the spotlight for the last decade, less is known about circulating tumor RNA (ctRNA). There are unanswered questions about why some tumors shed high amounts of ctNAs while others have undetectable levels. Also, there are gaps in our understanding of associations between tumor evolution and ctNA characteristics and shedding kinetics. In this review, we summarize current knowledge about ctNA biology and release mechanisms and put this information into the context of tumor evolution and clinical utility. Conclusions A deeper understanding of the biology of ctDNA and ctRNA may inform the use of liquid biopsies in personalized medicine to improve cancer patient outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Circulating tumor DNA (ctDNA), the major component used for liquid biopsy examination, is an important biomarker for tracking and analyzing cancerous mutations. 5 An enzymatic on/off switch-mediated assay can identify KRAS mutations in a normal background from an minimal amount ctDNA of peripheral blood. 6 Measuring the ctDNA of patients provides important information for the screening and diagnosis of a tumor and promotes the efficacy of monitoring and medication guidance.…”

Section: Introductionmentioning

confidence: 99%

“…In comparison with obtaining tumor tissue samples, the collection of peripheral blood is convenient, non‐invasive, and suitable for dynamic observation. Circulating tumor DNA (ctDNA), the major component used for liquid biopsy examination, is an important biomarker for tracking and analyzing cancerous mutations 5 . An enzymatic on/off switch‐mediated assay can identify KRAS mutations in a normal background from an minimal amount ctDNA of peripheral blood 6 .…”

Section: Introductionmentioning

confidence: 99%

KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…During recent years, liquid biopsies and cfDNA has been studied in relation to different tumors and other diseases (30, 31). Despite the theoretically high prevalence of PAs and the broad effect on the organism caused by these tumors (32, 33), there are no studies that would examine the usability of ctDNA in PA diagnostics and prognostics.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Possibility to Detect Circulating Tumor DNA From Pituitary Adenoma

et al. 2019

View full text Add to dashboard Cite

Objective: Circulating free DNA (cfDNA) in general and circulating tumor DNA (ctDNA) in particular is becoming an increasingly used form of liquid biopsy biomarkers. In this study, we are investigating the ability to detect ctDNA from the plasma of pituitary adenoma (PA) patients.Design: Tumor tissue samples were obtained from planed PA resections, before which blood plasma samples were taken. Somatic variants found in PA tissue samples were evaluated in related cfDNA, isolated from plasma samples.Methods: Sanger sequencing, as well as previously obtained whole-exome sequencing data, were used to evaluate somatic variants composition in tumor tissue samples. cfDNA was isolated from the same PA patients and competitive allele-specific TaqMan PCR and amplicon-based next-generation sequencing (NGS) approach were used for targeted detection of variants found in corresponding tumor tissue samples.Results: Using NGS-based analysis, we detected five out of 17 somatic variants in 40 to 60% of total reads, three variants in 0.50–5.00% of total read count, including GNAS c.601C>T, which was detected using ultra-deep NGS (1.78 million X) in 0.77% of amplicons reads. Nine variants were not detected. We also detected We were not able to detect variant found in PA tissue in cfDNA using cast-PCR, indicating that the portion of variant-containing ctDNA in total isolated cfDNA is too small to be detected with this method.Conclusions: For the first time, we demonstrate the possibility to detect somatic variants of PA in cfDNA isolated from patients' blood plasma. Whether the source of variant detected in cfDNA is PA should be further tested.

show abstract

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy

Cited by 11 publications

References 139 publications

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance

KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing

Evaluation of the Possibility to Detect Circulating Tumor DNA From Pituitary Adenoma

Contact Info

Product

Resources

About